StockData

Grace Therapeutics vs Rocket Pharmaceuticals

GRCE and RCKT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How GRCE and RCKT compare

Rocket Pharmaceuticals is the larger company, worth 6.4 times as much as Grace Therapeutics ($232M against $36.2M).

Grace Therapeutics scores higher on the StockData Score (8 against 3 for Rocket Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricGRCERCKT
Size and price
Market cap$36.2M$232M
Share price$1.72$2.11
Change, 1 year−43.8%−30.8%
Change, 5 years−79.2%−91.1%
Beta (5Y)0.642.32
Employees5202
StockData Score
Total score8 (better)3
Valuation score11
Growth score00
Performance score11
Health score6 (better)1
Dividend score00
Valuation
P/B0.8×0.6× (better)
FCF yield–−73.6%
Profitability
Return on equity−36.2%−4.8% (better)
Return on invested capital−39.3% (better)−180%
Financial health
Debt / equity0.00–
Interest coverage–−101.3×
Current ratio11.47 (better)9.24
Altman Z-score3.57 (better)−2.72
Piotroski F-score2 (better)1
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions18.8%90.9%
Held by insiders37.8%22.3%
Insider net buying, 12 months$839K (better)−$934K
Short interest, % of float12.7%19.0%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.